Lifeward Acquires Oramed Tech, Injects $47M in Capital

Event summary

  • Lifeward has acquired Oramed’s Protein Oral Delivery (POD™) technology.
  • The partnership provides Lifeward with access to up to $47 million in capital, receiving an initial $10 million on March 25, 2026.
  • Lifeward has made changes to its board of directors as part of the transaction.
  • The deal is positioned by Lifeward as a path to profitability and expansion into a large biotech market.

The big picture

Lifeward’s acquisition of Oramed’s POD™ technology represents a significant shift towards diversifying its biomedical innovation pipeline beyond its core rehabilitation technology offerings. The $47 million capital injection provides a short-term boost, but the long-term success depends on the technology’s clinical validation and integration into Lifeward’s existing business model. This move signals a desire to compete in a larger, more lucrative biotech market, but also introduces new execution risks.

What we're watching

Integration Risk
The success of this partnership hinges on Lifeward’s ability to effectively integrate Oramed’s POD™ technology into its existing product portfolio and operations, which could be complicated by differing corporate cultures and development timelines.
Capital Deployment
How Lifeward allocates the $47 million in capital will be a key indicator of the partnership’s strategic value; a focus on R&D versus marketing could signal different growth priorities.
Clinical Validation
The market’s reaction to clinical data generated using the POD™ technology will be crucial in determining the long-term value of the acquisition and its impact on Lifeward’s overall valuation.